Express Pharma

NOVEMBER 7, 2023

The type 2 diabetes (T2D) landscape has historically been dominated by insulin receptor (IR) targeting drugs. This condition disrupts glucose metabolism, resulting in high blood glucose levels and a variety of effects thereafter, such as an increased risk of stroke and diabetic neuropathy. IR’s role in T2D is well-defined.

Diabetes 111

Diabetes 111

Express Pharma

MARCH 2, 2025

Union Minister of Chemicals and Fertilizers, and Health and Family Welfare, Jagat Prakash Nadda inaugurated the weeklong celebrations of Jan Aushadhi Diwas, 2025 by flagging off the Rath (Chariot) and 10 other vehicles carrying the information about Pradhan Mantri Bhartiya Janaushadhi Pariyojana from Nirman Bhawan. to the citizens.

Generic Medicine 76

Generic Medicine Diabetes 76

STAT

OCTOBER 4, 2024

  The Medicare Advantage market is expected to grow in 2025, despite big changes from insurers , STAT reports.   Italian pharma company Recordati said it will buy from Sanofi the global rights to an approved drug to treat cold agglutinin disease , a rare autoimmune disorder, for $825 million, Reuters reports. 

Health Insurance Companies 283

Health Insurance Companies Diabetes 283

BioPharma Dive

JANUARY 2, 2025

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.

Diabetes 109

Diabetes 109

Express Pharma

DECEMBER 2, 2024

The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.

Labelling 126

Labelling Diabetes Drug Development 126

STAT

OCTOBER 15, 2024

Saxenda is an older drug of the same GLP-1 drug class as the company’s popular Ozempic diabetes treatment and Wegovy weight loss medication. Biocon is the first company to win U.K. authorization to offer a generic version of Novo Nordisk’s Saxenda weight treatment and is ready to launch sales by November.

Diabetes 275

Diabetes 275

The Pharmacist

JULY 4, 2023

Last week (27 June) the Department of Health and Social Care (DHSC) issued a Tier 3 (high impact) medicine […] The post GLP-1 receptor agonists shortage expected until 2025 appeared first on The Pharmacist.

Diabetes 98

Diabetes 98

Pharmacy Times

MARCH 23, 2025

In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s advantages in stroke prevention and weight loss vs SGLT2s superiority in heart failure, CV death reduction, and renal protection.

Diabetes 61

Diabetes 61

Pharmacy Times

MARCH 22, 2025

Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.

Diabetes 54

Diabetes 54

Pharmacy Times

JUNE 5, 2024

Body mass index is the main driver of type 2 diabetes globally, accounting for 52.2% of disability-adjusted life years.

Diabetes 50

Diabetes 50

Putting Patients First Blog

FEBRUARY 6, 2025

New Trusted Messengers Campaign Tackles Heart Disease, Diabetes and Obesity February 6, 2025 By: Leah Poffenberger, Senior Manager, Communications Millions of Americans are impacted by heart disease, diabetes, or obesityoften in tandem. As part of the roll-out of the new series, Chico-Jarillo and Snead joined Dr. Omar A.

Diabetes 52

Diabetes Communication 52

Drug Patent Watch

JANUARY 13, 2025

billion by 2025, growing at a CAGR of 34.2% from 2020 to 2025[1]. ” Diabetes: Addressing a Global Epidemic With diabetes affecting millions worldwide, the advent of biosimilar insulins has been particularly impactful. billion by 2025, driven by patent expirations and the need for cost-effective treatments.

Biosimilars 78

Biosimilars Diabetes 78

Express Pharma

MAY 6, 2024

The new nano carrier could help people with diabetes avoid side-effects linked to insulin injections such as hypoglycemia, inform the researchers Research led by the University of Sydney and Sydney Local Health District has developed a system using nanotechnology that could allow people with diabetes to take oral insulin in the future.

Diabetes 103

Diabetes 103

pharmaphorum

JUNE 8, 2021

US healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying diabetes-focused startup Steady Health. ” The post Carbon Health buys virtual diabetes clinic firm Steady Health appeared first on.

Diabetes 59

Diabetes Communication 59

Putting Patients First Blog

JANUARY 22, 2025

2025 Health Leadership Conference takes on The Future of Leadership January 22, 2025 By: Leah Poffenberger, Senior Manager, Communications Leadership health care often comes with unique challenges in an ever-changing ecosystem. To learn more about the 2025 Health Leadership Conference, visit the conference website.

Communication 52

Communication Diabetes Drug Development 52

PharmD Live

JANUARY 8, 2025

Medicares increasing focus on quality metrics in 2025 presents critical challenges for healthcare providers. Reporting Deadline: Data for the 2024 performance year must be submitted by March 31, 2025, to avoid penalties and secure incentives. This underscores the urgency of compliance in subsequent years.

Hospitals 52

Hospitals Diabetes 52

Pharma Marketing Network

NOVEMBER 15, 2024

Example: When marketing a new diabetes medication like Ozempic , your content should be tailored to answer specific questions patients or HCPs might have about the drug. What are the top platforms for pharma marketing in 2025? Pharma professionals should take the time to research and segment their audience.

Diabetes 52

Diabetes 52

PharmD Live

FEBRUARY 3, 2025

It involves coordinated care and patient education from healthcare providers to help individuals effectively manage conditions like diabetes, hypertension, and heart disease. As we look ahead to 2025, healthcare providers who invest in CCM programs will see not only improved patient outcomes but also enhanced operational efficiencies.

Medication Therapy Management (MTM) 52

Medication Therapy Management (MTM) Hospitals Nursing Homes Diabetes 52

Putting Patients First Blog

DECEMBER 12, 2024

Schroeder Stribling , President & Chief Executive Officer, Mental Health America, will serve as the Chair of the NHC Board of Directors for 2025. The NHC Board will be in excellent hands in 2025 under Schroeder Striblings leadership as we launch our new three-year Strategic Plan, said Randall Rutta, the NHCs Chief Executive Officer.

Diabetes 40

Diabetes 40

Big Molecule Watch

FEBRUARY 7, 2025

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending the grant of marketing authorizationsforthree biosimilar productsAmgens PAVBLU and SKOJOY, and CuraTeQ Biologics DYRUPEG.

Biosimilars 59

Biosimilars Chemotherapy Diabetes 59

pharmaphorum

DECEMBER 4, 2022

AMG 133 is a bispecific molecule that addresses two targets, GLP-1 and GIPR, and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen. billion in 2025 once initial manufacturing problems are resolved. in those getting a 420 mg dose.

Diabetes 101

Diabetes 101

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

Packaging 111

Packaging Pharmaceutical Manufacturing Diabetes 111

Putting Patients First Blog

APRIL 10, 2025

In the campaign, an impressive group of grassroots leaders and community advocates shared insights about ways to reduce risk factors and improve health outcomes for chronic conditions.The discussions focused on heart disease, diabetes, and obesity three conditions that affect over 60 million Americans.

52

52

Express Pharma

MARCH 16, 2025

For example, companies like Biocon and Cipla have introduced affordable biosimilars and cost-effective versions of critical treatments for conditions such as diabetes and cancer. What are the top 3 trends to watch out for in 2025,which could have a disproportionate impact on the globaland Indian life sciences landscape?

Biosimilars 98

Biosimilars Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

APRIL 1, 2024

. “ABBV-RGX-314 [could] become a first-in-class gene therapy for wet AMD and the standard of care to treat and prevent progression of diabetic retinopathy,” stated Kenneth Mills, President and Chief Executive Officer of REGENXBIO. Regulatory submissions are expected in late 2025 through the first half of 2026, REGENXBIO confirmed.

Diabetes 98

Diabetes 98

European Pharmaceutical Review

MAY 14, 2024

In Lyon Gerland, Sanofi stated that it is investing €10 million to locate production of TZield ® , a biologic for type 1 diabetes, in France. Sanofi shared that it plans to launch in 2025. This investment will support 150 jobs. The facility will be low-carbon.

Vaccines 98

Vaccines Packaging Diabetes 98

pharmaphorum

JULY 13, 2021

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. billion by 2025. All told, the deal could be worth up to $1.2 According to analysts at GlobalData – sales are set to rocket to $3.5

Diabetes 98

Diabetes 98

Putting Patients First Blog

FEBRUARY 13, 2025

Guest Blog: Shining a Light on Liver Health During Black History Month February 13, 2025 By: Ivory Allison, National Senior Director, Community Impact, American Liver Foundation Black history is rich with stories of resilience, innovation, and advocacy in the face of systemic health disparities.

Diabetes 58

Diabetes 58

Big Molecule Watch

JULY 9, 2024

According to the press release, PYZCHIVA will be available in the United States beginning on February 22, 2025, pursuant to a settlement and license agreement between Samsung Bioepis and Janssen Biotech Inc.

Biosimilars 50

Biosimilars Diabetes 50

Pharmaceutical Technology

JUNE 7, 2023

The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Phase III trial.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025.

Diabetes 98

Diabetes Labelling Immunization Immunity 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025.

Diabetes 98

Diabetes Labelling Immunization Immunity 98

pharmaphorum

APRIL 28, 2022

The US pharma has just reported top-line results from the first phase 3 trial of its dual GLP-1/GIP agonist tirzepatide as an obesity therapy that back up earlier results showing it can reduce the weight of people with diabetes. billion in 2025, twice its earlier forecast. of their body weight, compared to 2.4%

Diabetes 52

Diabetes 52

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. The company made a $75m up-front cash payment to EyePoint Pharmaceuticals on the closure of the deal, and an additional $7.5m will be paid in equal quarterly instalments in 2024.

Diabetes 52

Diabetes Drug Development 52

Big Molecule Watch

FEBRUARY 24, 2025

On February 18, 2025, Alvotech and Teva Pharmaceuticals (Teva) announced that the U.S. AVT06 is an aflibercept biosimilar candidate for the treatment of eye disorders such as neovascular (wet) age-related macular degeneration (AMD), macular edema, and diabetic retinopathy.

Biosimilars 45

Biosimilars Diabetes 45

pharmaphorum

DECEMBER 21, 2020

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

pharmaphorum

OCTOBER 6, 2022

Lilly already has approval for the dual GLP-1/GIP agonist under the Mounjaro brand name as a diabetes therapy and is tipped to make rapid inroads in that market, with EvaluatePharma predicting sales could break the $1 billion barrier in 2024, and $3 billion two years later. billion in 2025 sales.

Diabetes 52

Diabetes 52